Select Location
We need your delivery location to continue browsing
Prescription Required
Aprazer Healthcare Pvt Ltd
30 capsule
Lenvatinib
Keep in cold place
Delivering To:
Overview
Lenvakast 10mg capsules are classified as anticancer medications. Patients with specific forms of advanced or progressing thyroid cancer are the main patients treated with these medications. In the human body, cancer cell development is unchecked and uncontrolled. Early-stage cancer diagnosis is challenging. Only the disease's symptoms can be lessened when it is discovered in its advanced stages. As part of combination therapy, lentakast capsules are usually given in combination with another anticancer medication to treat various cancer types.
Thyroid Cancer
Differentiated Thyroid cancer
Treatment of Kidney Cancer
Liver cancer
Treatment of Endometrial Cancer
The human body shows undesired symptoms after taking the Lenvakast 10mg capsule. Usually, they disappear with time as the body adjusts to the medicine. These side effects don't need special medical attention. It is advised to consult your doctor if these symptoms become unmanageable.
Some of the common side effects of Lenvakast capsule are mentioned below:
Nausea
Fatigue
Diarrhea
Vomiting
Headache
Weight loss
Loss of appetite
Changes in taste
Joint pain or muscle pain
Stomach pain or discomfort
Hypertension (high blood pressure) Serious side effects:
Blood clotting
Kidney failure
Heart problems
Hypothyroidism
Poor wound healing
Liver toxicity or failure
Hemorrhage (bleeding)
Skin reactions (rash or blisters)
Lenvakast 10mg capsule is a prescription-based anticancer drug that should be administered orally. It is advised to take this capsule after consulting your healthcare expert.
Lenvakast 10mg capsule works by blocking the action of the enzyme Receptor tyrosine kinases (RTKs). This enzyme helps develop new blood vessels that nourish cancer cells and help them multiply. Lenvakast blocks the function of receptors that aid the growth of blood vessels in cancer cells. This helps slow the expansion of the disease to different parts of the body and eventually reduces the size of the tumor.
Alcohol
consult your doctor
The interaction of alcohol with this drug is still unknown. It is advisable not to consume alcohol while taking Lenvakast 10mg capsule. It is advised to consult your doctor for further information.
Pregnancy
consult your doctor
Lenvakast 10mg capsule may be considered unsafe during pregnancy. Please consult your doctor in such condition.
Breast Feeding
consult your doctor
Lenvakast 10mg capsule is probably not safe if you're breastfeeding. Kindly consult your doctor.
Driving
unsafe
It is advisable not to drive or operate heavy machinery as you may feel dizzy after taking Lenvakast 10mg capsule.
Kidney
safe if prescribed
Share your medical history with your healthcare expert in case of kidney disease before taking Lenvakast 10mg capsule.
Liver
safe if prescribed
Inform your doctor before starting Lenvakast 10mg capsule if you have liver disease to avoid any serious side effects.
It is advised not to miss any scheduled dosage of Lenvakast 10mg capsule. In case you miss a dose, consult your doctor immediately.
Don't overdose to compensate for the missed one. Contact your doctor or any healthcare provider and seek medical attention immediately in such cases.
Go for a healthy and balanced diet while taking this medicine to support overall health and well-being.
It is advised to avoid heavy-duty activities or exercise till the time you get an idea of how Lenvakast is affecting you.
Avoid eating grapefruits or any products which has grapefruit as it affects the absorption rate of Lenvakast 10mg capsule.
It is advised to use effective birth control methods and avoid pregnancy during the treatment with this capsule.
Monitor your blood sugar & pressure, Kidney & Liver function (KFT & LFT), Heart function at proper intervals after taking Lenvakast.
Swelling of hands, lips, and weight gain are some of the side effects observed after taking Lenvakast 10mg capsule. To reduce them, the doctor may suggest some medication.
If you experience any kind of symptoms after taking Lenvakast capsules, like unexplained bruising or bleeding, sore throat, mouth ulcers, high temperature (fever), or other signs of infection, it is important to inform your doctor as soon as possible.
This medicine should not be given to children under the age of 18.
Yes, vision problems may be observed after taking this medicine as a potential side effect. It is advised if you notice such changes, you inform your doctor immediately.
Yes, hair loss can be observed while undergoing treatment with Lenvakast 10mg Capsule. Patients should discuss the side effects with their doctor before starting treatment.
This medicine increases the risk of high blood pressure, which may increase the risk of heart problems. It is important to check your blood pressure regularly while taking this medicine.
Lenvakast increases the risk of bleeding, and during any procedure that involves cutting or removing tissue, may increase this risk further. So, it is advised to inform your dentist or doctor that you're taking medicine.
There are chances that this medicine can disturb the menstrual cycle and may affect fertility in women in the long term. It is important to discuss such concerns with your doctor before starting Lenvakast.
French JD, Haugen BR, Worden FP, Bowles DW, Gianoukakis AG, Konda B, Dadu R, Sherman EJ, McCue S, Foster NR, Nikiforov YE, Farias TDJ, Norman PJ, Wirth LJ.(2024). Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers. Clin Cancer Res 30(17), 3757-3767.
Ruicci, K.M., Deng, Y., Xiao, T. et al. Real-world treatment outcomes and clinicopathologic and molecular determinants of response to first-line lenvatinib in patients with advanced follicular cell-derived thyroid cancer. (2025). BJC Rep 41(3).
Sharma, S., Nazar, A. H., Mishra, P., et al. (2025). A new therapeutic paradigm: Radioiodine combined with lenvatinib for radioiodine‑avid metastatic well‑differentiated thyroid cancer. Nuclear Medicine Communications.
Soll, D., Bischoff, P., Frisch, A. et al. (2024). First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study. BMC Endocr Disord.
Yokota T, Hamauchi S, Kawakami T, Fushiki K. (2024). Lenvatinib rechallenge after failure of lenvatinib and sorafenib in metastatic thyroid cancer. Invest New Drugs 361-368.
Yu, Z., Leng, B., You, R., et al. (2025). Lenvatinib plus immunotherapy versus lenvatinib monotherapy in lenvatinib‑insensitive patients with unresectable hepatocellular carcinoma: A retrospective study. Investigational New Drugs, 43(1), 93–100.